Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Conditioning Regimens

Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant

Bone Marrow Transplantation volume 48, pages 646–650 (2013)Cite this article

Subjects

Abstract

I.v. BU plus fludarabine is an effective conditioning regimen for myeloid neoplasias with low treatment-related mortality. At standard doses, cutaneous toxicity has been reported in <5% of cases. As we observed a much higher incidence of cutaneous toxicity in patients who received predominantly pharmacokinetically based doses of BU, we performed a retrospective analysis of 61 patients who received i.v. BU plus fludarabine (+/− antithymocyte globulin; ATG) as a conditioning regimen before allogeneic PBSC transplant. Of the 58 evaluable patients, 33 (57%) developed cutaneous toxicity that fell within the spectrum of toxic erythema of chemotherapy (TEC). The median onset of TEC was 22 days and most patients had multiple sites of involvement, with the groin, axillae and palms/soles being the favored sites. In men, scrotal involvement, sometimes severe, was also commonly observed. Initially, allergic reactions to antibiotics, fungal infections and GVHD were also considered until the clinical presentation of TEC became well recognized. In all patients, the skin healed without specific therapy but resolution often required several weeks. This series suggests that TEC is common after BU/fludarabine+/− ATG and it is important for transplant physicians to recognize, particularly as misdiagnosis could lead to inappropriate treatment.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Andersson BS, de Lima M, Thall PF, Wang X, Couriel D, Korbling M et al. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant 2008; 14: 672–684.

    Article  CAS  Google Scholar 

  2. Bredeson CN, Zhang MJ, Agovi MA, Bacigalupo A, Bahlis NJ, Ballen K et al. Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 993–1003.

    Article  CAS  Google Scholar 

  3. Chunduri S, Dobogai LC, Peace D, Saunthararajah Y, Quigley J, Chen YH et al. Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both? Bone Marrow Transplant 2008; 41: 935–940.

    Article  CAS  Google Scholar 

  4. de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004; 104: 857–864.

    Article  CAS  Google Scholar 

  5. Russell JA, Tran HT, Quinlan D, Chaudhry A, Duggan P, Brown C et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002; 8: 468–476.

    Article  CAS  Google Scholar 

  6. Russell JA, Irish W, Balogh A, Chaudhry MA, Savoie ML, Turner AR et al. The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia. Biol Blood Marrow Transplant 2010; 16: 509–514.

    Article  CAS  Google Scholar 

  7. Kröger N, Bornhäuser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG et al. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Ann Hematol 2003; 82: 336–342.

    Article  Google Scholar 

  8. Santarone S, Pidala J, Di Nicola M, Field T, Alsina M, Ayala E et al. Fludarabine and pharmacokinetic-targeted busulfan before allografting for adults with acute lymphoid leukemia. Biol Blood Marrow Transplant 2011; 17: 1505–1511.

    Article  CAS  Google Scholar 

  9. Kerbauy FR, Rodrigues M, de Souza Santos FP, Sobrinho JN, Kutner JM, Torres MA et al. Allogeneic hematopoietic stem cell transplant after intravenous busulfan and fludarabine conditioning. Leuk Lymphoma 2011; 52: 321–324.

    Article  CAS  Google Scholar 

  10. Geddes M, Kangarloo SB, Naveed F, Quinlan D, Chaudhry MA, Stewart D et al. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. Biol Blood Marrow Transplant 2008; 14: 220–228.

    Article  CAS  Google Scholar 

  11. Hamadani M, Craig M, Phillips GS, Abraham J, Tse W, Cumpston A et al. Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning. Hematol Oncol 2011; 29: 202–210.

    Article  CAS  Google Scholar 

  12. Pidala J, Kim J, Anasetti C, Kharfan-Dabaja MA, Nishihori T, Field T et al. Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia. J Hematol Oncol 2010; 3: 36.

    Article  Google Scholar 

  13. Ryu SG, Lee JH, Choi SJ, Lee YS, Seol M, Hur EH et al. Randomized comparison of four-times-daily versus once-daily intravenous busulfan in conditioning therapy for hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007; 13: 1095–1105.

    Article  CAS  Google Scholar 

  14. Russell JA, Duan Q, Chaudhry MA, Savoie ML, Balogh A, Turner AR et al. Transplantation from matched siblings using once-daily intravenous busulfan/fludarabine with thymoglobulin: a myeloablative regimen with low nonrelapse mortality in all but older patients with high-risk disease. Biol Blood Marrow Transplant 2008; 14: 888–895.

    Article  CAS  Google Scholar 

  15. Bolognia JL, Cooper DL, Glusac EJ . Toxic erythema of chemotherapy: a useful clinical term. J Am Acad Dermatol 2008; 59: 524–529.

    Article  Google Scholar 

  16. Ikeda H, Kawano H, Kitaura T, Kimura A, Kihira K . Acral erythema associated with high-dose methotrexate infusion. Ann Pharmacother 1999; 33: 646.

    CAS  PubMed  Google Scholar 

  17. Hellier I, Bessis D, Sotto A, Margueritte G, Guilhou JJ . High-dose methotrexate-induced bullous variant of acral erythema. Arch Dermatol 1996; 132: 590–591.

    Article  CAS  Google Scholar 

  18. Feizy V, Namazi MR, Barikbin B, Ehsani A . Methotrexate-induced acral erythema with bullous reaction. Dermatol Online J 2003; 9: 14.

    PubMed  Google Scholar 

  19. Beri R, Chunduri S, Sweiss K, Peace DJ, Mactal-Haaf C, Dobogai LC et al. Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen. Bone Marrow Transplant 2010; 45: 249–253.

    Article  CAS  Google Scholar 

  20. Morgan M, Dodds A, Atkinson K, Szer J, Downs K, Biggs J . The toxicity of busulphan and cyclophosphamide as the preparative regimen for bone marrow transplantation. Br J Haematol 1991; 77: 529–534.

    Article  CAS  Google Scholar 

  21. Hoy SM, Lyseng-Williamson KA . Intravenous busulfan: in the conditioning treatment of pediatric patients prior to hematopoietic stem cell transplantation. Paediatr Drugs 2007; 9: 271–278.

    Article  Google Scholar 

  22. Crider MK, Jansen J, Norins AL, McHale MS . Chemotherapy-induced acral erythema in patients receiving bone marrow transplantation. Arch Dermatol 1986; 122: 1023–1027.

    Article  CAS  Google Scholar 

  23. Azurdia RM, Clark RE, Friedmann PS . Chemotherapy-induced acral erythema (CIAE) with bullous reaction. Clin Exp Dermatol 1999; 24: 64–66.

    Article  CAS  Google Scholar 

  24. Burgdorf WH, Gilmore WA, Ganick RG . Peculiar acral erythema secondary to high-dose chemotherapy for acute myelogenous leukemia. Ann Intern Med 1982; 97: 61–62.

    Article  CAS  Google Scholar 

  25. Levine LE, Medenica MM, Lorincz AL, Soltani K, Raab B, Ma A . Distinctive acral erythema occurring during therapy for severe myelogenous leukemia. Arch Dermatol 1985; 121: 102–104.

    Article  CAS  Google Scholar 

  26. Lokich JJ, Moore C . Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 1984; 101: 798–799.

    Article  CAS  Google Scholar 

  27. Perkins JB, Kim J, Anasetti C, Fernandez HF, Perez LE, Ayala E et al. Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012; 18: 1099–1107.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine (Hematology), Yale University School of Medicine, New Haven, CT, USA

    T L Parker, D L Cooper & S E Seropian

  2. Department of Dermatology, Yale University School of Medicine, New Haven, CT, USA

    J L Bolognia

Authors
  1. T L Parker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D L Cooper
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S E Seropian
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J L Bolognia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T L Parker.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Parker, T., Cooper, D., Seropian, S. et al. Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant. Bone Marrow Transplant 48, 646–650 (2013). https://doi.org/10.1038/bmt.2012.218

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2012.218

Keywords

This article is cited by

Search

Advanced search

Quick links